Quantum Genomics accelerates clinical development of QGC101 in Congestive Heart Failure
​uantum Genomics, developing cutting-edge drugs addressing unmet medical needs in the field of cardiovascular diseases, announced it would accelerate the clinical development of QGC101 in Congestive Heart Failure (CHF). Originally planned in 2017, the phase 2a clinical study has now been scheduled to begin in mid- 2016. This decision was taken after successfully demonstrating efficacy in animal models. This preclinical study in dogs was performed by Quantum Genomics' partner, a major animal health pharmaceutical company responsible for assessing the drug potential. Under the terms of the agreement signed in 2014, the pharmaceutical partner has 6 months to exercise an option to further develop and market the drug in the field of animal health, which could provide recurring revenues to Quantum Genomics. Considering the new clinical program in congestive heart failure in humans, and the pending option for QGC101 licensing agreement in animal health, we increased our valuation of Quantum Genomics to €12.66/share.
Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.